Complete and sustained objective response per RECIST to Irvalec (PM02734) in undifferentiated large cell esophageal adenocarcinoma: A case report and a review of the literature.

Abstract

Undifferentiated large cell carcinoma is a rare entity in esophageal cancer and very few data are available in the literature on this uncommon histological subtype. We report a case of a 58-year-old Caucasian male previously treated with cisplatin/5-fluorouracil, docetaxel and carboplatin/plitidepsin who received treatment with a novel antitumor agent, Irvalec (PM02734), as fourth line. The patient received treatment from July 2006 to July 2009, a total of 49 cycles, at a dose of 2.4 mg/m(2) as a 24-hour infusion every 3 weeks. He did not present severe complications or unplanned or cumulative toxicities. Complete and durable response according to RECIST was reported. He was alive at the last follow-up on March 2012.

• Authors: Ramón Salazar, Carmen Cuadra, Marta Gil-Martín, Andrea Vandermeeren, Vicente Alfaro, Cinthya Coronado
• Journal: Case reports in oncology (Case Rep Oncol) Vol. 5 Issue 2 Pg. 354-8 (May 2012) ISSN: 1662-6575 [Electronic] Switzerland
• PMID: 22807904 (Publication Type: Case Reports)